Insomnia symptoms occur in about 33% to 50% of the adult population [
Sleep consists of two phases:[
The stages of sleep occur in a repeated pattern or cycle of NREM followed by REM, with each cycle lasting approximately 90 minutes. The sleep cycle is repeated four to six times during a 7- to 8-hour sleep period.[
The Sleep Disorders Classification Committee of the American Academy of Sleep Medicine has identified five major categories of sleep disorders:[
In this summary, unless otherwise stated, evidence and practice issues as they relate to adults are discussed. The evidence and application to practice related to children may differ significantly from information related to adults. When specific information about the care of children is available, it is summarized under its own heading.
Cancer patients are at great risk of developing insomnia and disorders of the sleep-wake cycle. Insomnia, the most common sleep disturbance in this population, is most often secondary to physical and/or psychological factors related to cancer and/or cancer treatment.[
Sleep disturbances may be exacerbated by paraneoplastic syndromes associated with steroid production and by symptoms associated with tumor invasion, such as:
Sleep disturbance can also vary by diagnosis. In a study of patients with melanoma (n = 124), breast cancer (n = 124), and endometrial cancer (n = 82),[
|Cancer Type||Minimally Symptomatic||Insomnia-Predominant||Very Sleepy With Upper Airway Symptoms||Symptomatic With Severe Dysfunction|
Differences by disease groups may be associated with treatment regimens and/or other factors.
Medications—including vitamins, corticosteroids, neuroleptics for nausea and vomiting, and sympathomimetics for the treatment of dyspnea—and other treatment factors can negatively impact sleep patterns.
Side effects of treatment that may affect the sleep-wake cycle include the following:[
Sustained use of the following can cause insomnia:
In addition, withdrawal from the following substances may cause insomnia:
Hypnotics can interfere with rapid eye movement (REM) sleep, resulting in increased irritability, apathy, and diminished mental alertness. Abrupt withdrawal of hypnotics and sedatives may lead to symptoms such as:
REM rebound is a marked increase in REM sleep, with increased frequency and intensity of dreaming, including nightmares.[
The sleep of hospitalized patients is likely to be frequently interrupted by treatment schedules, hospital routines, and roommates, which singularly or collectively alter the sleep-wake cycle. Other factors influencing sleep-wake cycles in the hospital setting include patient age, comfort, pain, anxiety, environmental noise, and temperature.[
Consequences of sleep disturbances can influence outcomes of therapeutic and supportive care measures.[
Assessment is the initial step in managing sleep disturbances in people with cancer. Assessment data should include the following:[
The sections below outline recommendations for a sleep history and physical examination. Data can be retrieved from multiple sources, such as:[
The Insomnia Severity Index, which has been validated in adult oncology populations, is recommended when screening for insomnia in clinical settings.[
The diagnosis of insomnia is primarily based on a careful, detailed medical and psychiatric history. The American Academy of Sleep Medicine has produced guidelines for the use of polysomnography as an objective tool in evaluating insomnia. The routine polysomnogram includes the monitoring of the following:
Polysomnography is the major diagnostic tool for assessment of sleep disorders. It is indicated in the evaluation of suspected sleep-related breathing disorders and periodic limb movement disorder, when the cause of insomnia is uncertain, or when behavioral or pharmacological therapy is unsuccessful.[
Sleep disturbances have been shown to change throughout the cancer trajectory, which supports the need to assess sleep throughout the patient's cancer experience. One descriptive study [
Sleep disturbances frequently co-occur with cancer-related fatigue and may have common underlying mechanisms. Prospective and multidimensional assessments of these two symptoms were conducted in a study involving patients who were newly diagnosed with stage I through stage IIIA breast cancer (N = 152).[
In addition, stress can contribute to sleep disturbance. A study of 957 patients undergoing chemotherapy treatment for breast, lung, gastrointestinal, or gynecological cancer measured responses to validated stress/resilience assessment instruments (14-item Perceived Stress Scale, 22-item Impact of Event Scale-Revised, 30-item Life Stressor Checklist-Revised, and 10-item Connor-Davidson Resilience Scale). Compared with patients classified in a normative or resilient class, patients in the stressed class had significantly higher levels of sleep disturbance. Also, each of the domains of sleep disturbance within the validated 21-item GSDS (quantity, quality, sleep onset latency, mid-sleep awakening, early awakenings, and excessive daytime sleepiness) and use of medications to help with sleep were statistically significant and crossed clinically meaningful cutoff points for patients in the stressed class.[
Risk Factors for Sleep Disorders
Characterization of Sleep
Management of sleep disturbances should focus on treatment of problems such as:
Other areas to manage include symptoms from cancer and its treatment and the identification and management of environmental and psychological factors. When sleep disturbances are caused by symptoms of cancer or its treatment, measures that control or alleviate symptoms are often the key to resolving sleep disturbances. Management of sleep disturbances combines nonpharmacological and pharmacological approaches individualized for the patient.
Nonpharmacological Management of Sleep Disturbances
Many people who experience insomnia have poor sleep hygiene (such as smoking and drinking excessive alcohol just before bedtime), which can exacerbate or perpetuate insomnia.[
Sleep hygiene in an inpatient setting involves modifying the sleep environment to decrease sleep disruption. Minimizing noise, dimming or turning off lights, adjusting room temperature, and consolidating patient care tasks to reduce the number of interruptions can increase the amount of uninterrupted sleep.[
Cognitive strategies include:[
Behavioral strategies include:
Both of these strategies seek to limit the time spent in bed that does not involve sleeping.[
Components of CBT-I include the following:
Relaxation therapy can be used to achieve both behavioral and cognitive outcomes, particularly when it is combined with imagery. Educational objectives around sleep hygiene are also used to treat insomnia and include content on the following:[
Practice guidelines from the American Academy of Sleep Medicine clearly state that multicomponent therapy is recommended over single therapies. Because of insufficient evidence about its efficacy, sleep hygiene education is not recommended as a single-modality management approach; other reviews state that sleep hygiene by itself is not effective.[
Several trials and meta-analyses have shown CBT-I to be at least as effective as conventional pharmacological therapies in treating primary chronic insomnia but without side effects.[
A four-arm study (conducted in patients with primary chronic insomnia) that evaluated zolpidem versus CBT versus zolpidem and CBT versus placebo reported a greater effect (P = .05) on sleep-onset latency for both groups involving CBT (change of 44%) versus the group receiving zolpidem alone (change of 29%).[
There are limited data evaluating elements of CBT-I in cancer survivors, and most data are about women with breast cancer. However, there have been at least four randomized controlled trials of CBT-I in cancer survivors.[
Most studies using active control arms were in breast cancer survivors. One study compared CBT-I with sleep education and hygiene in 72 women,[
In the second study, 219 women were randomly assigned to a behavioral therapy group consisting of stimulus control, general sleep hygiene (limiting naps, going to bed and rising at consistent times), and relaxation or to a healthy-eating education control group. The interventions were delivered by trained nurses in person, 2 days before the initiation of chemotherapy, before each chemotherapy treatment, and 30 days after the last chemotherapy treatment. The nurses worked with women assigned to behavioral therapy to individualize and reinforce the behaviors. The Pittsburgh Sleep Quality Index (PSQI) was used to measure subjective sleep quality, complemented by use of a sleep diary and wrist actigraph. Sleep quality significantly improved in the group receiving behavioral therapy, compared with the control group. These differences were also seen in data from the sleep diary and actigraph, with both showing significantly fewer awakenings in the behavioral therapy group.[
In some places, patients may not have access to in-person, professionally delivered CBT-I. A randomized controlled trial conducted with breast cancer survivors demonstrated that CBT-I delivered via digital media can also produce meaningful clinical improvements, although improvements are not as robust as those produced with professionally delivered CBT-I. This three-armed trial compared video-based CBT-I (VCBT-I) and professionally delivered CBT-I (PCBT-I) with a no-treatment control group in 242 breast cancer survivors. Both the VCBT-I and PCBT-I groups had significantly greater improvements in diary-measured sleep variables, compared with the control group. The patients in the PCBT-I group reported greater improvements in some sleep outcomes and in fatigue and depression levels than did the VCBT-I group.[
|Reference||Cancer Type||Sample Size and Design||Control and CBT-I Intervention||Measures||Outcomes|
|ISI = Insomnia Severity Index; PCBT-I = professionally administered CBT-I; PSQI = Pittsburgh Sleep Quality Index; QOL = quality of life; RCT = randomized controlled trial; VCBT-I = video-based CBT-I.|
|a Actigraphy: A technique that uses a small instrument called an actigraph (a watch-like sensory unit) worn on the wrist or ankle to measure body gross motor activity. It is helpful in determining sleep patterns and daytime activity.|
|b Polysomnography: A test used to diagnose sleep disorders on the basis of sleep-related biophysiological changes.|
|Berger et al., 2009[
||Breast (stages I–III) during chemotherapy||N = 219; RCT||Control: Healthy-eating group (sessions with equal time, attention)||PSQI, sleep diary, actigraphya, fatigue assessment||Significant improvement in sleep quality and nighttime awakenings for CBT group, compared with control group|
|CBT-I: Individualized plan before chemotherapy, stimulus control, modified sleep restriction, relaxation therapy, sleep hygiene|
|Epstein et al., 2007[
||Breast (stages I–III)||N = 72; RCT||Control: Sleep education and hygiene||Sleep diary, actigraphy, ISI||Both groups improved over time; significant improvement between groups favored CBT-I group in time to fall asleep, time awake after sleep onset, total sleep time, sleep quality (as measured by ISI)|
|CBT-I: 6 sessions, stimulus control, sleep restriction, sleep education and hygiene|
|Espie et al., 2008[
||Mixed||N = 150; RCT||Control: Sleep education and hygiene||Sleep diary; actigraphy; fatigue, depression/anxiety, and QOL assessments||Significant improvement in time to fall asleep, time awake after sleep onset, sleep efficiency, fatigue, specific QOL outcomes for CBT-I group, compared with control group|
|CBT-I: 5 weekly sessions, stimulus control, sleep restriction, cognitive restructuring|
|Savard et al., 2005[
||Breast (stages I–III)||N = 57; RCT||Control: Wait list||Sleep diary; polysomnographyb; ISI; fatigue, depression/anxiety, and QOL assessments||Significant improvement in time to fall asleep, time awake after sleep onset, sleep efficiency, depression/anxiety, and QOL outcomes for CBT group, compared with control group|
|CBT-I: 8 weekly sessions, stimulus control, sleep restriction, sleep education and hygiene, cognitive restructuring, fatigue management|
|Savard et al., 2014[
||Breast (stages I–III)||N = 242; RCT||Control: No treatment (n = 81)||Sleep diary; ISI; actigraphy; fatigue, depression/anxiety, and QOL assessments||Compared with control group, PCBT-I and VCBT-I groups associated with significant improvement in sleep diary–measured sleep variables; compared with VCBT-I group, PCBT-I group had more improvement in sleep, fatigue, and depression/anxiety outcomes and had higher remission rates for insomnia|
|PCBT-I (n = 81): 6 weekly sessions|
|VCBT-I (n = 80): 60-min animated video, 6 booklets|
|CBT-I content: Similar for both groups (stimulus control, sleep restriction, sleep education and hygiene, cognitive restructuring)|
Inpatient nonpharmacological management
CBT delivered by psychologists has shown promise for the treatment of insomnia in patients with cancer.[
A study conducted in cancer survivors demonstrated the benefits of a specialized yoga program to improve sleep quality and reduce medication use. A total of 410 cancer survivors with moderate to severe sleep disturbances were randomly assigned to receive standard care or standard care plus a 4-week yoga intervention delivered in two weekly sessions by trained yoga instructors. The yoga participants showed significant improvement in sleep quality, daytime dysfunction, nighttime awakening, and sleep efficiency, compared with standard-care participants. One major limitation of this study was its limited population generalizability, as most study participants were female, White, married, and well-educated breast cancer survivors. Another major limitation was the lack of an adequate control group with respect to nonspecific effects such as group support and attention.[
Exercise interventions have shown positive effects on subjective and objective sleep quality in patients with cancer. A study conducted in Taiwanese patients with lung cancer investigated the effects of a 12-week exercise intervention on sleep quality and rest-activity rhythms.[
Over time, the walking exercise group showed significant improvement in subjective sleep quality (lower PSQI scores) compared with the usual-care group. The walking exercise group also showed improvement in total sleep time (TST), an important objective measure of sleep quality, compared with the usual-care group. Additionally, the positive effects on TST (i.e., increase in TST) were greater in patients with poor rest-activity rhythm at baseline, suggesting more benefits in patients with poor circadian sleep-activity rhythms. The limitations of the study included a lack of blinding, hence a possible placebo effect in the intervention group. Also, despite randomization, the mean amount of baseline moderate physical activity was higher in the usual-care group than in the intervention group.
Other actions or interventions that may promote rest in the hospital or extended-care setting include the following:[
Psychological interventions are directed toward facilitating the patient's coping processes through education, support, and reassurance. As the patient learns to cope with the stresses of illness, hospitalization, and treatment, sleep may improve.[
Pharmacological Management of Sleep-Wake Cycle Disturbances
When cancer survivors experience sleep-wake disturbances, cognitive behavioral intervention counseling should be the first consideration for management. For more information, see the Nonpharmacological Management of Sleep Disturbances section. Resources for education and training in CBT may not be readily available in many cancer centers; therefore, community resources need to be investigated. If CBT is not available or has not been successful, pharmacological management can be considered. In addition, when patients have comorbidities contributing to sleep-wake cycle disturbances (such as hot flashes, uncontrolled pain, anxiety, depression, or other mood disturbances),[
Despite the lack of evidence in cancer populations, clinicians widely use pharmacological interventions. Therefore, the following discussion of pharmacological agents and recommendations for use is based on evidence from studies conducted in patients with primary insomnia and clinical experience.[
Several classes of medications are used to treat sleep-wake cycle disturbances, including the following:
Drug characteristics to consider before a drug is chosen to treat an individual patient include the following:
These pharmacokinetic principles are important to match the agent to the type of sleep disturbance (e.g., problems falling asleep versus problems staying asleep). There are also safety issues to be considered, such as potentials for tolerance, abuse, dependence, withdrawal (including risk of rebound insomnia), and drug-drug and drug-disease interactions. Medications for sleep-wake cycle disturbances should be used short term and/or as needed.
General considerations for the use of hypnotics
Medications used to induce sleep are intended for the short-term management of sleep disorders. The use of these medications for longer periods is poorly studied. They are usually combined with lifestyle changes that reinforce good sleep habits and negate the need for chronic hypnotic medications.
Most research studies of current and historic hypnotic medications rarely exceed a duration of 12 to 16 weeks. Additionally, no current hypnotic re-creates normal sleep architecture, and variations from normal periods of rapid eye movement (REM) sleep and non-REM sleep are common. It is important to taper hypnotic medications slowly, or the variations in normal sleep patterns can become even more pronounced, with the majority of time spent in REM sleep in a condition known as REM rebound.[
Table 3 lists the drug categories and specific medications, including doses, commonly used to treat sleep disturbances.
|CR = controlled-release; FDA = U.S. Food and Drug Administration; REM = rapid eye movement.|
|Nonbenzodiazepine benzodiazepine receptor agonist||zaleplon (Sonata)||5–20 mg||Useful for problems falling asleep only.||[
|zolpidem tartrate (Ambien)||5–10 mg||Useful for problems falling asleep only. Maximum suggested dose for women: 5 mg.||[
|zolpidem tartrate extended-release (Ambien CR)||6.25–12.5 mg||Biphasic release; useful for problems both falling asleep and staying asleep. Do not crush or split tablets. Maximum suggested dose for women: 6.25 mg.||[
|eszopiclone (Lunesta)||1–3 mg||Useful for problems both falling asleep and staying asleep. Do not take with or right after meal.||[
|Benzodiazepine||clonazepam (Klonopin)||0.25–2 mg||Used for REM sleep disorder (not FDA approved).||[
|lorazepam (Ativan)||0.5–4 mg; dose >2 mg rare||Risk of loss of motor coordination, falls, and cognitive impairment.||[
|temazepam (Restoril)||7.5–30 mg||Risk of loss of motor coordination, falls, and cognitive impairment.||[
|Melatonin receptor agonist||ramelteon (Rozerem)||8 mg||Useful for problems falling asleep only. Little negative effect on cognition, somnolence, motor coordination, or nausea.||[
|Antihistamine||diphenhydramine (Benadryl)||25–100 mg||Useful for problems falling asleep only. Anticholinergic side effects; increases delirium risk in older patients.||[
|hydroxyzine (Vistaril, Atarax)||10–100 mg||Useful for problems falling asleep only. Anticholinergic side effects; increases delirium risk in older patients.||[
|Tricyclic antidepressant||doxepin (Silenor)||3–6 mg||Lower doses used for treatment of primary insomnia when antidepressant effect not needed. Risk of anticholinergic side effects and weight gain.||[
|amitriptyline (Elavil)||10–25 mg||Lower doses used for treatment of primary insomnia when antidepressant effect not needed. Risk of anticholinergic side effects and weight gain.||[
|nortriptyline (Pamelor)||10–50 mg||Risk of anticholinergic side effects and weight gain.||[
|Second-generation antidepressant||trazodone (Desyrel)||25–100 mg||Risk of orthostatic hypotension and falls.||[
|mirtazapine (Remeron)||7.5–45 mg||If depression not a concern, 7.5–15 mg best for sleep, hot flashes, increased appetite, and less morning sedation. Risk of falls.||[
|Antipsychotic||quetiapine (Seroquel)||25–100 mg||Risk of weight gain, metabolic syndrome, abnormal/involuntary movements; possible cardiovascular effects (e.g., prolonged QT interval). Generally not a preferred agent due to side effects.||[
|Chloral derivative||chloral hydrate||500–1,000 mg||Used mainly for sleep maintenance. Risk of gastric irritation, dependence, and withdrawal. Lethal in overdose.||[
Nonbenzodiazepine benzodiazepine receptor agonists
All agents in this class are FDA approved for primary insomnia. These agents promote sleep by enhancing the effects of gamma-aminobutyric acid (GABA) at the GABA type A (GABAA) receptor. Unlike traditional benzodiazepines, these agents preferentially target specific GABAA receptor subtypes. Zolpidem and zaleplon bind predominantly to the alpha-1 subtype of GABAA, and eszopiclone preferentially targets the alpha-3 receptor subtype. This selective receptor subtype targeting has both advantages and disadvantages. These agents have mainly hypnotic/sedative effects and lack the anxiolytic, anticonvulsant, and myorelaxant effects seen with benzodiazepines. Conversely, because of the selective receptor subtype targeting, these agents have fewer effects on cognitive and psychomotor function and carry less risk of tolerance, dependence, and withdrawal (especially physical withdrawal) than benzodiazepines.[
These agents may be preferred for use in patients with cancer when only hypnotic effects are desired and should be taken just before bedtime (or even in bed) because they enter the brain very quickly. Some of these agents (e.g., zaleplon) have a short elimination half-life. Because of their longer-lasting effects, zolpidem extended-release and eszopiclone are preferred in the treatment of difficulty staying asleep. However, these agents carry a higher risk of residual morning sedation and cognitive/motor impairments than do agents with shorter elimination half-lives (e.g., zaleplon and immediate-release zolpidem).
Benzodiazepines target several GABAA receptor subtypes, including alpha-1, -2, -3, and -5, and work by enhancing GABA effects at these receptors. In addition to hypnotic/sedative effects, these agents also have anxiolytic, anticonvulsant, and myorelaxant effects. Benzodiazepines are preferred when other effects (such as antianxiety or muscle relaxation) are desirable with or without the hypnotic effects.[
Benzodiazepines carry a much higher risk of tolerance, dependence, and withdrawal than nonbenzodiazepine receptor agonists. Benzodiazepine withdrawal has been associated with the risk of seizures, delirium tremens, autonomic instability, and death. These agents should be used with extreme caution and close monitoring in patients with histories of significant substance use because of potential tolerance and dependence issues. Benzodiazepines have also been associated with cognitive impairment and difficulties with motor coordination.
Generally, benzodiazepines with longer half-lives (e.g., clonazepam) are associated with a higher risk of residual morning sedation and cognitive/motor impairments. Agents with shorter elimination half-lives (e.g., lorazepam) are generally preferred for short-term anxiolytic effects and difficulties falling asleep and in older patients. Agents with longer half-lives (e.g., clonazepam) are preferred for the treatment of persistent anxiety and difficulties falling and staying asleep. All benzodiazepines are associated with risk of respiratory depression and should be used with caution in patients with preexisting respiratory disorders.
Melatonin receptor agonists: Ramelteon and tasimelteon
Ramelteon and tasimelteon work by binding to the melatonin receptor types MT1 and MT2. Ramelteon is useful only for the treatment of difficulties falling asleep and does not have any other effects, such as anxiolytic or myorelaxant effects. Tasimelteon is indicated for use in circadian sleep disorder. These agents do not treat difficulties staying asleep but also carry much less risk of cognitive/motor impairments and dependence.[
Diphenhydramine and hydroxyzine decrease arousal by blockading histamine receptors. Antihistamines are sold over the counter and are useful for treating difficulties in falling asleep only. There is limited evidence for the use of antihistamines to treat insomnia; these agents are used when traditional hypnotics or benzodiazepines are less suitable because of the risk of cross-dependence or other issues, such as vulnerability of a patient to addictions. The anticholinergic properties of antihistamines may also be beneficial in the treatment of nausea and vomiting. The sedative and anticholinergic properties of these agents increase the risk of delirium, especially in older patients.[
Sedating antidepressants are considered first-line agents when insomnia is comorbid with depression/anxiety symptomatology. These drugs include tricyclic antidepressants (e.g., amitriptyline) and second-generation antidepressants (e.g., mirtazapine). The sedating effects of tricyclic antidepressants are caused mainly by histamine receptor blockading and partially by blockading of 5-HT2 and muscarinic receptors. The sedating effects of mirtazapine are caused by its blocking of 5-HT2 and histamine receptors, while those of trazodone are caused by its blocking actions at the at histamine, 5-HT, and noradrenaline receptors.[
Tricyclic antidepressants have a small therapeutic window and can be lethal in overdose, compared with second-generation antidepressants such as mirtazapine. Additionally, tricyclics carry other risks, such as weight gain, anticholinergic side effects, and cardiovascular side effects, and should be used under close supervision. These agents sometimes are used in low doses (see Table 3) as adjuncts to other antidepressants to treat insomnia comorbid with depression/anxiety. This helps to avoid the side effects associated with higher doses while delivering the needed sedating effects. Tricyclics can also boost appetite and may be the treatment of choice for insomnia in patients with comorbid cachexia. Certain tricyclics (amitriptyline and nortriptyline) can also be beneficial in the treatment of pain syndromes (e.g., neuropathic pain) and headaches when these issues are comorbid with insomnia. Low doses of antidepressants (subtherapeutic for depression) are frequently used to treat insomnia without any comorbidities.
Mirtazapine has appetite-stimulating and antiemetic properties in addition to sedating effects. It is frequently used in insomniac patients with depression (therapeutic dose for depression, 15–45 mg) or without depression (subtherapeutic dose for depression, 7.5–15 mg) with comorbid nausea or loss of appetite. In low doses, trazodone (50–100 mg) can promote sleep and is often combined with other antidepressants (e.g., fluoxetine 20 mg in the morning) in depressed patients with insomnia.
Antipsychotics such as quetiapine have sedating effects caused mainly by the blockade of histamine receptors. However, these agents should be considered as a last resort and as a short-term treatment because of their serious side-effect profile. The use of antipsychotics has been associated with the following:
Antipsychotics can be considered for treatment-refractory insomnia, especially with comorbid anxiety symptomatology.[
Chloral derivative: Chloral hydrate
Chloral hydrate has sleep-promoting effects resulting from its effects on GABA systems. It is associated with risk of withdrawal symptoms similar to those of benzodiazepines and with rapid development of tolerance. Additionally, chloral hydrate carries the risk of gastric irritation and multiple drug interactions, and it is lethal in overdose. Like antipsychotics, chloral hydrate is usually considered only in cases of treatment-refractory insomnia because of its serious side-effect profile and the availability of safer alternatives.[
Melatonin, a hormone produced by the pineal gland during the hours of darkness, plays a major role in the sleep-wake cycle and has been linked to the circadian rhythm. A review found that short-term use of melatonin appears to be safe; however, the studies were not conducted in the context of cancer therapy.[
Evidence suggests that circulating melatonin levels are significantly lower in physically healthy older people and in insomniacs than in age-matched control subjects. In view of these findings, melatonin replacement therapy may be beneficial in the initiation and maintenance of sleep in older patients.[
Melatonin may interact with certain chemotherapeutic regimens via the cytochrome P450 enzyme and other systems.[
Clinical studies in individuals with renal, breast, colon, lung, and brain cancer suggest that melatonin exerts anticancer effects in conjunction with chemotherapy and radiation therapy; however, evidence remains inconclusive.[
No studies have been conducted to specifically evaluate the effects of Cannabis inhalation or other Cannabis products in patients with primary or secondary sleep disturbances. Limited data from in vitro studies, animal studies, and small populations of healthy individuals or chronic Cannabis users are beginning to elucidate some of the relationships among various neurotransmitters, the sleep-wake cycle, and related effects of Cannabis pharmacology.[
Cannabis-based medicines are under development as a treatment for chronic pain syndromes, including cancer-related pain. One such medication is nabiximols (Sativex), an oromucosal formulation (delta-9-tetrahydrocannabinol and cannabidiol mixed in a 1:1 ratio). Studies conducted with nabiximols, primarily focusing on pain syndromes, have shown improvement in subjective sleep quality when sleep was measured as a secondary outcome.[
Current Clinical Trials
Use our advanced clinical trial search to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. General information about clinical trials is also available.
The Patient With Pain
Since enhanced pain control improves sleep, appropriate analgesics or nonpharmacological pain management should be administered before introducing sleep medications. Tricyclic antidepressants can be particularly useful for the treatment of insomnia in patients with neuropathic pain and depression. Patients on high-dose opioids for pain may be at increased risk for the development of delirium and organic mental disorders. Such patients may benefit from the use of low-dose neuroleptics as sleep agents (e.g., haloperidol 0.5–1 mg).
The Older Patient
Older patients frequently have insomnia due to age-related changes in sleep. The sleep cycle in this population is characterized by lighter sleep, more frequent awakenings, and less total sleep time. Anxiety, depression, loss of social support, and a diagnosis of cancer are contributory factors in sleep disturbances in older patients.[
Sleep problems in older adults are so common that nearly one-half of all hypnotic prescriptions written are for people older than 65 years. Although normal aging affects sleep, the clinician should evaluate the many factors that cause insomnia, such as:[
Nonpharmacological treatment of sleep disorders is the preferred initial management, with the use of medication when indicated and referral to a sleep disorder center when specialized care is necessary.[
Providing a regular schedule of meals, discouraging daytime naps, and encouraging physical activity may improve sleep. Hypnotic prescriptions for older patients must be adjusted for variations in metabolism, increased fat stores, and increased sensitivity. Dosages should be reduced by 30% to 50%. Problems associated with drug accumulation (especially flurazepam) must be weighed against the risks of more severe withdrawal or rebound effects associated with short-acting benzodiazepines. An alternate drug for older patients is chloral hydrate.[
Sleep Apnea After Mandibulectomy
Anterior mandibulectomy can result in the development of sleep apnea. All patients with head and neck tumors who have had extensive anterior oral cavity resection should be evaluated before decannulation of the tracheostomy tube. Subsequent flap and/or reconstruction of the lower jaw seems to prevent the development of sleep apnea. In contrast, facial sling suspension of the lower lip does not prevent the development of sleep apnea.[
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Howell et al. as reference 33.
This summary is written and maintained by the PDQ Supportive and Palliative Care Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® Cancer Information for Health Professionals pages.
Purpose of This Summary
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the pathophysiology and treatment of sleep disorders. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.
Reviewers and Updates
This summary is reviewed regularly and updated as necessary by the PDQ Supportive and Palliative Care Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Board members review recently published articles each month to determine whether an article should:
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
The lead reviewers for Sleep Disorders are:
Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's Email Us. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.
Levels of Evidence
Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Supportive and Palliative Care Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.
Permission to Use This Summary
PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as "NCI's PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary]."
The preferred citation for this PDQ summary is:
PDQ® Supportive and Palliative Care Editorial Board. PDQ Sleep Disorders. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: https://www.cancer.gov/about-cancer/treatment/side-effects/sleep-disorders-hp-pdq. Accessed <MM/DD/YYYY>. [PMID: 26389467]
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.
The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Managing Cancer Care page.
More information about contacting us or receiving help with the Cancer.gov website can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the website's Email Us.
Last Revised: 2023-08-25
This information does not replace the advice of a doctor. Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
Individual and family medical and dental insurance plans are insured by Cigna Health and Life Insurance Company (CHLIC), Cigna HealthCare of Arizona, Inc., Cigna HealthCare of Illinois, Inc., Cigna HealthCare of Georgia, Inc., Cigna HealthCare of North Carolina, Inc., Cigna HealthCare of South Carolina, Inc., and Cigna HealthCare of Texas, Inc. Group health insurance and health benefit plans are insured or administered by CHLIC, Connecticut General Life Insurance Company (CGLIC), or their affiliates (see
All insurance policies and group benefit plans contain exclusions and limitations. For availability, costs and complete details of coverage, contact a licensed agent or Cigna sales representative. This website is not intended for residents of New Mexico.